Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘daiichi sankyo’

T Cell Engager Comeback: Why solid tumors may finally yield

While most eyes at ASCO will be on the marquee phase 3 ADC readouts, a quieter revolution may be unfolding in the T cell engager space.

Created by Wall-E from a Blue Ice Publishing prmpt

After years of struggling to replicate hematologic successes in solid tumours – and several high-profile failures that nearly killed the field – a new generation of engineered bispecifics is finally showing signs of life.

The question is whether these sophisticated molecular machines can overcome the fundamental challenges, which have made solid tumour bispecifics such a graveyard for promising compounds.

In this latest review we take a look at some early-stage agents, some of which are looking quite encouraging while others might struggle with headwinds…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Early Developmental Therapeutics Trends from ESMO 2024

The ESMO 2024 database currently houses over 1,820 poster titles, with no abstracts available for review yet.

In the absence of detailed insights, sifting through the massive trove for gems in Developmental Therapeutics becomes both a challenge and an opportunity.

What’s cookin’ this week in the BSB kitchen?

We’ve scoured the listings and curated a selection of promising early-stage therapies that could signal emerging trends or novel approaches.

In this preview – our sixth from ESMO24 – we explore intriguing clinical leads in the ongoing quest to address unmet clinical needs in oncology…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Pointing the way in AML

Pointing the way from Balboa Park

We held off from discussing the Menin inhibitors in AML at ASH last month because we were waiting for Kura’s update in the relapsed/refractory and upfront settings, as well as their initial combination data.

Now is a good time to take another snapshot in time.

The good news is there are some initial data reported on the first twenty patients in Kura Oncology’s KOMET-007 trial, which includes a mix of Menin-naive, previously treated patients who have received Menin inhibitors, as well as those the front-line setting who received combination treatment with standard chemotherapy.

When looked in the context of the prior data, an intriguing body of evidence is now emerging in this space, where a raft of other competitors are also rapidly emerging to compete with Kura Oncology and Syndax.

I came away with a number of impressions from the webcast, here are our takeaways…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Oncology trends and directions to watch out for in 2022

Proof that the sun came on a Wednesday in England this winter – hard not to be upbeat on days like this!!

As we continue our journey looking forward in 2022 and beyond, it’s time to start putting some meat on the bones, so to speak, in terms of what specifically we can look forward to hearing more about.

January brings a renewed sense of hope, despite the dreary weather in many places around the world, even in the Blighty the sun sometimes shines (right).

With this uplifting comes a fresh sense of new directions too, which is as true for both life in general as it is for oncology R&D.

With this in mind, in our latest review, we highlight six key areas to watch out for and explain why we are interested in following them with regards to early oncology new product development…

BSB subscribers can read up on our ongoing commentary and analysis on oncology new product development – you can either log-in or click to access the back story behind the latest innovations!

This content is restricted to subscribers

Why do some FLT3 inhibitors work in AML and some don’t?

Oncology R&D is tough and there are many more failures than successes, despite the FDA approving more than they’ve rejected over the last two years. That’s quite unusual in my experience.

Dr Mario SznolAs Dr Mario Sznol (Yale) told us at SITC recently, sometimes these things are sometimes more whimsical. He was referring to different types of modalities that can be used in conjunction with cancer immunotherapies, but the sentiment is also highly relevant to the FLT3 AML space.

The critical questions we need to think here about are:

  1. What’s different about the various approaches?
  2. What can we learn from the FLT3 experiences to date that give us clues about the changing landscape in AML?

To learn more about FLT3 AML and where this field is going, subscribers can login or you can purchase our commentary and insights…

This content is restricted to subscribers

error: Content is protected !!